Growth Metrics

Celularity (CELU) Current Deferred Revenue (2020 - 2025)

Celularity has reported Current Deferred Revenue over the past 6 years, most recently at $8.3 million for Q3 2025.

  • Quarterly results put Current Deferred Revenue at $8.3 million for Q3 2025, up 31.84% from a year ago — trailing twelve months through Sep 2025 was $8.3 million (up 31.84% YoY), and the annual figure for FY2024 was $6.3 million, up 3.9%.
  • Current Deferred Revenue for Q3 2025 was $8.3 million at Celularity, up from $3.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for CELU hit a ceiling of $11.9 million in Q1 2021 and a floor of $2.8 million in Q2 2024.
  • Median Current Deferred Revenue over the past 5 years was $4.5 million (2023), compared with a mean of $5.6 million.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 72.08% in 2021 and later surged 34.2% in 2024.
  • Celularity's Current Deferred Revenue stood at $4.1 million in 2021, then rose by 10.45% to $4.5 million in 2022, then skyrocketed by 34.02% to $6.0 million in 2023, then rose by 3.9% to $6.3 million in 2024, then soared by 33.46% to $8.3 million in 2025.
  • The last three reported values for Current Deferred Revenue were $8.3 million (Q3 2025), $3.5 million (Q2 2025), and $3.5 million (Q1 2025) per Business Quant data.